a Center for Global Health , Universidad Peruana Cayetano Heredia , Lima , Peru.
b School of Veterinary Medicine , Universidad Nacional Mayor de San Marcos , Lima , Peru.
Expert Rev Anti Infect Ther. 2019 Jan;17(1):51-56. doi: 10.1080/14787210.2018.1555241. Epub 2018 Dec 10.
Oxfendazole (methyl [5-(phenylsulphinyl)-1H benzimidazole-2-yl] carbamate) has a particularly long metabolic half-life in ruminants, and its metabolite fenbendazole also has anthelminthic action. A very limited number of drugs are available for the treatment of some zoonotic helminth infections, such as neurocysticercosis and echinococcosis. More recent work has expanded oxfendazole's nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites. Areas covered: The present article reviews evidence supporting the safety and efficacy of oxfendazole against both gut and tissue dwelling helminths in animals, as well as more recent safety and pharmacokinetic data supporting its potential for use in human parasitoses. Expert commentary: The pharmacokinetics, safety, and wide spectrum of efficacy of oxfendazole are consistently demonstrated in intestinal helminth infections of animals as well as in tissue dwelling larval cestode and trematode infections in diverse animal species. Now supported by first-in-human safety and pharmacokinetic data, oxfendazole becomes a promising alternative to the limited portfolio of antiparasitic drugs available to treat helminthic diseases of humans.
奥芬达唑（[5-（苯基亚磺酰基）-1H 苯并咪唑-2-基]氨基甲酸甲酯）在反刍动物中有特别长的代谢半衰期，其代谢产物芬苯达唑也具有驱虫作用。目前，可用于治疗一些人畜共患寄生虫感染的药物非常有限，如脑囊虫病和包虫病。最近的研究工作扩展了奥芬达唑的非临床安全性概况，并在健康人类志愿者中证明了其安全性和生物利用度，从而为治疗土壤寄生虫和组织寄生虫的驱虫治疗提供了一种新的、非常需要的选择。
本文综述了支持奥芬达唑在动物中针对肠道和组织寄生虫的安全性和疗效的证据，以及最近支持其用于人类寄生虫病的安全性和药代动力学数据。
奥芬达唑的药代动力学、安全性和广谱疗效在动物的肠道寄生虫感染以及不同动物物种中的组织内幼虫绦虫和吸虫感染中得到了一致的证明。现在，有了人体安全性和药代动力学数据的支持，奥芬达唑成为了治疗人类寄生虫病的有限驱虫药物组合的一种有前途的替代品。
